Full Year
ACB — FY2026 (Year to March 2026) Financial Report Analysis
Aurora Cannabis grew FY2026 net revenue 11% to C$320.6M on European medical sales, but swung to a C$58.6M IFRS loss from continuing operations and negative free cash flow, and guides FY2027 lower after a Canadian reimbursement cut.